Podcasts about Median

This episode explores Americans' financial well-being in 2025, using a Yahoo Finance/Marist survey as the springboard. Don and Tom discuss how their audience differs from the average American listener, how perceptions of financial health can be misleading, and what to actually do if your finances—or your feelings about them—are getting worse. They debate the usefulness of net worth tracking, stress the importance of financial literacy, and suggest automating savings. Listener questions cover indexed annuities, bond substitutes, tax implications, and long-term care sales pitches. They also read a letter defending Rick Edelman and challenging their dismissal of crypto, which leads to a lively discussion about evidence-based investing, Eugene Fama's critique of Bitcoin, and the dangers of sensationalized advice. They end with a reflection on public criticism and the value of having one's views challenged. 0:29 Comparing TRM listeners to Ramsey and Kiyosaki audiences 1:37 Median savings for over-65 Americans and why $200k still isn't enough 2:42 Yahoo/Marist survey results: affordability, debt, emergency savings 3:50 One in three say finances worsened; generational breakdown 4:51 Explaining net worth, what to include and exclude 7:01 Tracking net worth annually as a financial benchmark 8:00 Divorce, net worth, and the joke about “kill them off” 9:50 Income gap, gender differences, and perception vs. reality 10:34 How uncertainty and fear shape financial outlooks 11:41 Producer note joke about being “sexist but not leftist” 11:50 Dissatisfaction with savings and personal spending habits 13:06 Fixing bad finances: literacy, automation, benchmarking 17:20 Don argues perception matters more than reality for many 18:20 Listener question: fixed index annuity as bond substitute 19:46 Caps, participation rates, and underperformance vs. markets 21:10 Tax treatment of annuities vs. ETFs 22:55 Importance of advice near retirement (decumulation phase) 23:44 Listener shares bad LTC/annuity sales pitch experience 24:54 Fixed annuity guarantees vs. CDs and government bonds 25:39 Listener defends Rick Edelman, suggests an open dialogue 26:52 Don's critique of Edelman's shift toward sensationalism 29:29 Eugene Fama's comments on Bitcoin, clash with Edelman's stance 31:23 Public criticism is fair game—reading recent Apple Podcast reviews 32:48 Bitcoin adoption debate and institutional incentives Learn more about your ad choices. Visit megaphone.fm/adchoices

Hnutí Stačilo! by podle srpnového volebního modelu agentury Median získalo 9 procent hlasů. Podle bývalého místopředsedy KSČM Jiřího Dolejše ale levice v těchto volbách propásla svou šanci. „Hnutí Stačilo! nepovažuji za levici. Je to takový podivný slepenec s krajní pravicí, který je v podstatě zaměřený destruktivně,“ rozebírá Dolejš.

Hnutí Stačilo! podle posledního průzkum agentury Median stoupá voličská podpora. Zatímco preference vedoucího hnutí ANO podle stejné agentury klesají a preference SPD, Starostů a koalice Spolu stagnují, Stačilo! posílilo na 9 procent. „Jde o data z poloviny srpna. Novější průzkumy ukazují, že by se do Sněmovny dostalo, ale s o hodně nižším ziskem,“ uvádí politický analytik Deníku N Jan Tvrdoň.

A Tulsa ordinance to crack down on homelessness gets the mayor's signature.Oklahoma wants to jam cellphones in its jails and prisons.A new non-profit is working to fill OKC's Crossroads Mall with services for the community.You can find the KOSU Daily wherever you get your podcasts, you can also subscribe, rate us and leave a comment.You can keep up to date on all the latest news throughout the day at KOSU.org and make sure to follow us on Facebook, Tik Tok and Instagram at KOSU Radio.This is The KOSU Daily, Oklahoma news, every weekday.

The FOMC cut interest rates by 25bps, which was widely expected by markets. Additionally, median projections for a path forward indicate 50bps worth of cuts coming later in 2025. Kevin Hincks helps investors digest the market reactions and explains what the initial report means heading into Fed chair Jerome Powell's press conference.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

M

Elul is the 12th and final month of the Jewish calendar year. Elul Unbound is a Judaism Unbound initiative all about making Elul meaningful, through creative digital modalities. In this episode, Lex Rofeberg and Wendie Bernstein Lash explore the notion of chiasm (for "what is a 'chiasm' -- which is a great question -- click here), along with what it has to do with the month of Elul and the broader 7-year Shmita cycle. This Elul podcast is the third in a mini-series of four that are being released as part of Elul Unbound 2025 (our 26th-29th Elul episodes overall).--------------------------------------To check out all our Elul bonus episodes from previous years, which can still be relevant to your experience of Elul this time around, click here. Join our bi-weekly journey through Elul Unbound 2025 by signing up at this link, and sign up for our Elul Unbound Shabbat gatherings here, where we will be forging our kavanot (intentions) for the new year in real time with fellow Unbounders.If you're enjoying Judaism Unbound, please help us keep things going with a one-time or monthly tax-deductible donation -- support Judaism Unbound by clicking here!

Opening Reflections and California Concerns The AgNet News Hour began with hosts Nick Papagni and Lorrie Boyer sharing lighthearted Friday greetings before shifting to California's serious agricultural challenges. Papagni noted worsening Central Valley air quality caused by wildfires, likening the smoke to winter fog. He warned that tensions between state and federal governments over forest management may intensify as fall approaches. Boyer added that federal intervention could even extend to California's 2028 Olympic preparations. Policy Spotlight: Mexican Wolf Debate Boyer reported on a House Natural Resources Subcommittee hearing on the Enhancing Safety for Animals Act of 2025. The legislation would delist the Mexican wolf from the Endangered Species Act, a move supported by the National Cattlemen's Beef Association, the Arizona and New Mexico Cattle Growers Associations, and the Public Lands Council. Tom Patterson, President-elect of the New Mexico Cattle Growers Association, testified that wolf populations have shifted from a livestock concern to a community safety threat, citing attacks on pets, horses, and even children. In regulatory news, the EPA declined stricter wastewater rules for meat and poultry processors, concluding that current Clean Water Act requirements suffice. The National Chicken Council applauded this decision as a balanced approach to water quality regulation. Immigration Reform and the Dignity Act The program's central feature was an interview with Manuel Cunha, President of the Nisei Farmers League, who addressed farm labor shortages and immigration policy. He highlighted the bipartisan Dignity Act (H.R. 4393), introduced by Rep. María Elvira Salazar (R-FL) and Rep. Veronica Escobar (D-TX), as the most promising reform since the early 2000s. The Act includes a three-pronged approach: Long-Term Residents – renewable work authorization cards with penalties for undocumented status. Legal Pathways for New Workers – stronger background checks and legal entry channels. Criminal Entrants – removal of individuals linked to crime or gang activity. Cunha emphasized that the Act also provides protections for Dreamers and addresses Social Security benefits for long-term contributors who have paid into the system for decades. Coyotes, Fear, and Fake Documents Cunha warned about coyotes—human smugglers who charge up to $15,000 per person and often supply migrants with fraudulent documents. Workers fall into debt while employers unknowingly hire with false credentials. He called the system a “disaster” and urged growers to pressure congressional leaders like David Valadao, Jim Costa, Jimmy Panetta, and Vince Fong to support the Dignity Act. Despite federal assurances, many farmworkers still live in daily fear of deportation. Some alter their appearance to avoid suspicion, while enforcement remains concentrated in large metropolitan sanctuary cities. Farm Labor: Hard Work Few Will Do Papagni stressed that farm labor is not unskilled work, pointing to strawberry, lettuce, melon, and table grape harvesting as examples requiring years of expertise. Cunha agreed, noting that domestic welfare recipients are unlikely to take on such demanding jobs—something proven during the 1996–1998 Welfare to Work Program. With many long-time workers nearing retirement and fewer young people entering agriculture, Cunha pressed for a comprehensive guest worker program. A Call to Action Cunha's message to farmers and ag communities was clear: contact your congressional representatives and urge support for the Dignity Act. He highlighted Vince Fong as a key California lawmaker yet to sign on. If passed, the bill would initiate a five- to six-month rule-writing process, during which workers would receive documentation verifying employment, providing immediate protection while regulations are finalized. Farm Income and Market Updates According to the U.S. Economic Research Service (ERS): Net farm income in 2025 is projected at $179.5 billion, up 40.7% from 2024—the second-highest on record. Median farm household income, however, is projected to decline by $1,189 in 2025, reflecting weaker off-farm earnings. Government payments are forecast at $40.5 billion, the highest since 2020. The dairy sector is also strengthening, with exports reaching 18.7% of domestic production in June—the highest since 2022. Domestic yogurt consumption rose 12.2%, while overall use of milk solids grew 3%. Competitiveness and Global Pressures Papagni noted the difficulty of competing with countries paying $10–20 per day compared to California's $16 per hour wages, combined with stricter U.S. regulations. Boyer emphasized that despite higher costs, U.S. agriculture provides the world's safest and most affordable food supply, thanks largely to immigrant labor. Citrus Greening and Global Potato Trends Rick Dantzler of the Citrus Research and Development Foundation reported promising progress in the fight against citrus greening disease. Oxytetracycline trunk injections are showing strong results, with healthier canopies and improved fruit quality, though production costs rose 7%. Meanwhile, the global frozen potato market has shifted dramatically. Between 2019 and 2024, China and India moved from net importers to exporters of frozen fries and processed potato products, expanding markets into Asia and the Middle East. Criminal Provisions in the Dignity Act The legislation also strengthens criminal enforcement, including: Tougher penalties for illegal re-entry after multiple deportations. DNA testing to confirm family ties. Stricter penalties for voting by non-citizens. Increased minimum penalties for child sex trafficking. Boyer linked these provisions directly to combating coyote networks and broader exploitation. Wrapping Up The episode closed with Papagni and Boyer urging farmers to engage in the policy debate, follow updates at AgNetWest.com, and recognize that immigration reform is essential to keeping U.S. agriculture competitive and sustainable.

City Manager Brian Johnson joins host Rico Figliolini on Peachtree Corners Life for a practical update on projects shaping the city's next few years. He walks through the newly developed Simpsonwood Park master plan—designed to keep the park passive and natural while adding ADA-friendly access, renovated bathrooms, an updated chapel, selective forestry management, and a modest river overlook. Johnson also explains why the city is outsourcing maintenance of the Peachtree Parkway median so residents finally see consistent, five-day-a-week care despite legacy design constraints.The episode dives into traffic and road fixes at East Jones Bridge and 141 (longer turn lanes, better alignment, and a right-turn slip lane), the ESPLOST renewal on the ballot, and the last phase of the Waterside development—now tracking at roughly half the density initially allowed and focused on equity (for-sale) housing. With candid context on what's been approved or denied since cityhood, plus how extended-stay conversions and the Housing Authority factor in, this conversation is a clear, chart-backed look at how Peachtree Corners balances growth with character.Key takeawaysSimpsonwood Park will remain a passive park—no ballfields, pickleball, mountain biking, or major programming.Plan includes ADA-accessible paved paths, renovated bathrooms (including one closer to the river), resurfaced parking, and a chapel renovation.Selective forestry and wildlife/erosion work will improve long-term health of the park.City is outsourcing median maintenance on Peachtree Parkway; crews will be dedicated five days a week for mowing, edging, litter removal, and plant adjustments.Median design differs from Johns Creek (at-grade vs. raised), which has made upkeep harder; outsourcing addresses consistency and appearance.East Jones Bridge & 141: entrance realignment, longer left-turn stacking, and a right-turn slip lane to move traffic more safely and quickly.No municipal election this cycle for three council seats (no challengers qualified), but ESPLOST renewal is on the county ballot.Waterside final phase moves forward with for-sale (equity) units; overall buildout drops from up to 916 approved units to ~450.Post-2012 housing approvals show a measured approach—some apartment proposals approved, many reduced to townhomes or denied.Extended-stay hotel issues are being addressed, including a supervised conversion to efficiency units via the Housing Authority.Timestamp:(00:03:29) Simpsonwood Park master plan details and community input.(00:09:55) Renovation of chapel, bathrooms, and forestry management plans.(00:15:27) Outsourcing median maintenance on Peachtree Parkway.(00:24:27) Election update and ESPLOST renewal.(00:27:03) Waterside development's final phase and reduced density.(00:30:12) East Jones Bridge road improvements and traffic flow changes.(00:36:37) Housing trends, multifamily approvals, and denials over time.(00:42:41) Extended stay hotel conversions and housing authority oversight.(00:45:47) Balancing growth, community resistance, and long-term city planning.

Wall St closed lower on Tuesday to kick off the September trading month in the red as investors took profits from the summer bull rally and hold concerns over tariff uncertainty after a federal appeals court on Friday ruled that most of Trump's global tariffs are illegal. The Nasdaq lost 0.82%, the S&P500 dropped 0.7% and the Dow Jones ended the day down 0.55%.In Europe overnight, markets tumbled amid a rise in bond yields and the prospect of further tariff uncertainty out of the US. The STOXX 600 fell 1.5%, Germany's DAX fell 2.2%, the French CAC lost 0.7% and, in the UK, the FTSE100 ended the day down 0.9%.Across the Asia region on Tuesday, market sentiment was hit by tariff uncertainty leading to a mixed session in the region. Japan's Nikkei rose 0.3%, India's Nifty 50 gained 0.3%, South Korea's Kospi Index rose 0.94%, and Hong Kong's Hang Seng ended the day down 0.5%.The local market started the new trading month lower with a 0.3% decline on Tuesday as investors digested the August reporting season showing a weaker outcome than expected for FY25 and repositioned portfolios for the tailwinds expected in FY26. Australia's August reporting season delivered weaker-than-expected results, with only 20-30 % of companies beating earnings expectations compared with more than 80% in the US. Median earnings downgrades of 3.6% outpaced upgrades of 2% locally.With some heavyweight market stocks trading ex-dividend yesterday and Wall St closed on Monday, investor moves were buoyed yesterday by strength among the banks and a rally among key commodity prices yesterday however this wasn't enough to boost the ASX to a green finish.Gold rose 1.4% to $3,496.24 per ounce, and silver surpassed $40 for the first time since 2011, driven by expectations the US Federal Reserve will cut interest rates in September, according to ANZ.Collin's Food (ASX:CKF) soared over 7% yesterday after posting a 6.7% rise in total sales for the first 18-weeks of FY26 and the KFC Australia operator also reaffirmed guidance for FY26 targeting underlying NPAT of low-mid teens.What to watch today:On the commodities front this morning, oil is trading 1.33% higher at US$65.49/barrel, gold is up 1.5% at US$3528/ounce and iron ore is up 0.71% at US$102.53/tonne.The Aussie dollar has weakened against the greenback to buy 65.13 US cents, 96.70 Japanese Yen, 46.82 British Pence, and 1 New Zealand dollar and 11 cents.Ahead of the midweek trading session the SPI futures are anticipating the ASX will open the day down a sharp 0.42% tracking global market uncertainty overnight.Trading ideas:Bell Potter has maintained a buy rating on Harvey Norman (ASX:HVN) and have increased the 12-month price target on the homewares retailer from $6.00 to $8.30 following the release of FY25 results beating expectations and a strong start to FY26 especially from within the Australian business.And Trading Central has identified a bearish signal on Supply Network (ASX:SNL) following the formation of a pattern over a period of 268-days which is roughly the same amount of time the share price may fall from the close of $36.02 to the range of $27.50 to $29.00 according to standard principles of technical analysis.

El modo de vida de Haces, Monreal, Gutiérrez Luna, Noroña, López Hernández y etcéteras que los acompañan, como que no encaja con la filosofía de la que habla la secretaria de Gobernación, Rosa Icela Rodríguez

Syksyn tuotantokausi alkaa! Tässä Mikä on tärkeää? -podcastin jaksossa keskustellaan miksi peräti 95% tekoälyprojekteista epäonnistuu (3:00) ja retail-median ostamisen helpottamisesta kv-esimerkin kautta sekä sen kasvumahdollisuuksista Suomessa (16:58). Kolmantena keskusteluaiheena on useamman brändin vakavat pohdinnat luopua peukku-sanan käytöstä alfa-pvp-huumeen takia (29:35). Tällä kertaa juontaja Santtu Kottilan ohella panelisteina markkinoinnin generalisti Jussi Ylävaara Diamonds Helsingiltä sekä toimistoyrittäjä Lasse Iskanius markkinointitoimisto Julkee x Lempeestä. Linkit jaksossa mainittuihin uutisiin:
 1)https://fortune.com/2025/08/18/mit-report-95-percent-generative-ai-pilots-at-companies-failing-cfo/ 2)https://www.adweek.com/commerce/advertisers-will-soon-be-able-to-buy-macys-media-network-through-amazon/ 3)https://www.hs.fi/suomi/art-2000011447525.html ***** Mikä on tärkeää? -podcast on MarkkinointiRadion ohjelma, jossa kammataan läpi ajankohtaisia ja jokaiselle markkinoijalle tärkeitä uutisia. Mukana on vakiopanelistien joukko, joista kaksi on kerrallaan ohjelman juontaja Santtu Kottilan vieraana. Jokainen panelisti tuo Kottilan lisäksi mukanaan ajankohtaisen ja merkittävän uutisen tai ilmiön, minkä tärkeyden ja merkityksen raati käsittelee. Joka viikko käydään siis läpi kolme tärkeää ja ajankohtaista aihetta. Lisätetoja Mikä on tärkeää? -podcastista saat esimerkiksi täältä:
www.mkollektiivi.fi/mika-on-tarkeaa Podcast toteutetaan yhteistyössä digimarkkinointitoimisto Tricklen, luova toimisto Diamonds Helsingin sekä markkinointitoimisto Julkee x Lempeen kanssa.

«A lot of things break with scale.»In our latest conversation with Mikkel Dengsøe, co-founder of SYNQ and former Head of Data, Ops and Financial Crimes at Monzo Bank, we explore the secrets behind effective scaling of data teams.Mikkel reveals surprising statistics based on his analysis of over 10,000 LinkedIn data points and valuable insights from Monzo's scaling journey, where the data team grew from 30 to over 100 people in just two years.We discuss the critical balance between central data teams and domain experts, the importance of career paths for individual contributors (not just managers), and how data professionals can succeed by building relationships with stakeholders who involve them early in strategic processes.Here are our key takeaways: Data TeamsThere are some high-level questions you need to ask yourself when building, structuring or scaling a new data teamThis includes how big the team should be, also relatively too your organizations size and other teams, how it should be composed and structured, etc.A good idea is to collect data to create a benchmark.Benchmarks can be hard to combine and are a moving target, but they are nevertheless valueable. Most importantly, you need to ask yourself: WHY do we need to scale our data team?Involve people actively in setting the goals based on your WHY.Mikkel collected over 10.000 data points from companies on Linkedin. Here's what he found: Median % of data people in companies out of overall staff is 1-4%.Data team relative to engineering team varies between 1 data person per 10 engineers to 1 in 3.From the benchmark it is evident that data governance roles only appear in lager companies.In marketplace companies the effect of data on the business value is easiest to track. Therefore they seem more willing to invest In data teams.Investment in data means investment in your business. The consequences of not investing in data will be tangible in your business.Find a risk based approach to data as well. At what level can you balance investment, outcome and risk?Be cautious of «pseudo-data teams» - teams in a Business unit that do kind-of data work, but are not aligned with the organization.Be clear on the skills and competencies you need. What is a data analyst? What does a data scientist do in your organization?It is important to have a clear and consistent internal career ladder. Make it visible and understandable what is expected from each role on your team and don't change these expectations too often.Create pulse checks to understand what people are happy about and what not.Scaling Data Teams«Golden Nugget Awards» to showcase good data work every month. These were added to a database, so every new employee could evaluate them to see what good looks like.Write down your progression framework to get clear about your ideas and how people excel in your organization.You can show open what work lead to promotions. That can be engaging for people to follow in these tracks.Hub-n-Spoke model, where people rotate in and out of the central team and the distributed teams.Citizen developer programs are a way for larger organizations to scale data work. But It bears risk related to data literacy.Don't try to enable everyone, but enable those that are motivated.«You shouldn't necessarily force people into management to progress.»Senior technical careers can ensure an advanced level of quality. Which is a different way of scaling your data team.You need a career ladder for professionals that is independent from management careers.Create rituals that make good work stand out.

On The BIG Show today, we discuss the MOM's Occupational Wage Survey! Check out the full article here: https://www.straitstimes.com/business/which-jobs-pay-the-highest-median-salaries-in-singapore Connect with us on Instagram: @kiss92fm @Glennn @angeliqueteo Producers: @shalinisusan97 @snailgirl2000See omnystudio.com/listener for privacy information.

Friends, there isn't much to say here other than we at the show always mourn the loss of loved ones, including a truck load of meat. Rest In Sauce. And if you spot a thing that shouldn't be, send it in to janesays@civicmedia.us and we might use it on the show! So join us Monday through Friday at 11:51 a.m. for “This Shouldn't Be A Thing!” or search for it on Spotify, Apple or wherever you get your podcasts. And thanks for listening!!

Israel on siirtynyt Gazan kaupungin valtaamista koskevan suunnitelman ensimmäiseen vaiheeseen. Asevoimien mukaan Israelilla on jo ote kaupungin laitamista. Seurauksia arvioi vieraileva johtava asiantuntija Olli Ruohomäki Ulkopoliittisesta instituutista. Yhdysvaltain presidentti Donald Trump koettaa edistää Ukrainan rauhanprosessia kiireellä ja sanoo jo seuraavan vaiheen häämöttävän. Mutta suostuuko Venäjän presidentti todella tapaamaan Ukrainan presidentin Volodymyr Zelenskyin - ja millä ehdoilla? Keskustelemassa professorit Katri Pynnöniemi ja Juhana Aunesluoma Helsingin yliopistosta. Kansanedustaja Eemeli Peltosen kuolema nosti itsemurhat jälleen suureksi puheenaiheeksi. Median toimintatapoja herkissä aiheissa arvioi viestinnän professori Johanna Sumiala Helsingin yliopistosta. Itsemurhien määrästä ja ehkäisemisestä keskustelevat päällikkö Marena Kukkonen Mieli ry:stä sekä tutkimusprofessori Timo Partonen THL:stä. Juontaja Markus Liimatainen, tuottaja Anna-Maria Haarala.

Series - An Exposition of Exodus Text - Exodus 2:15-22  by Nick Neves, pastor | Midweek Service | 08.20.25   Pastor Nick continues to show parallels between Moses and Jesus, who is the better Mediator that Moses' ministry anticipates. Jesus sojourned with us by taking upon Himself a human nature. Though Moses' time in Median was a humbling experience, God expertly used it to train him and ready him to serve as a godly leader over the covenant people. 

Filmwax Radio is proud to welcome 3 female documentary filmmakers to the podcast for their first time. First up is the filmmaker Wendy Lobel. "Anxiety Club" provides an intimate and humorous look at anxiety through the eyes and minds of some of the most brilliant comedians working today. Marc Maron, Tiffany Jenkins, Baron Vaughn, Aparna Nancherla, Mark Normand, Eva Victor and Joe List offer candid reflections on their relationship with anxiety through exclusive interviews, standup performances, sketch videos, therapy sessions, and everyday life. With rare access to private therapy sessions, the film follows comedian Tiffany Jenkins (a content creator with over 9 million followers) as she undergoes behavioral therapy, capturing the profound changes her treatment brings about. Others find support from alternative sources, such as world-renowned meditation expert Tara Brach, PhD, or the psychologist-in-residence at The Laugh Factory, or simply from mentors in the comedy community. All of the comedians in "Anxiety Club" have created standup or sketch material about their mental health that is not only funny but uniquely relatable and disarming to audiences. With comedy, vulnerability, and honesty, these comedians provide remarkable insight into anxiety - the most prevalent mental health disorder affecting an estimated 300 million people worldwide. Then filmmakers Steph Ching and Ellen Martinez with their PBS documentary "Slumlord Millionaire". Winner of the Audience Award at the 2024 DOC NYC Film Festival, “Slumlord Millionaire” explores the rapid gentrification of New York City neighborhoods and the housing crisis sweeping not only New York but the nation. Median rents nationwide are higher than ever, and in Manhattan, the average rent is now almost $5,000 per month. As rents increase, some landlords have become aggressive in getting long-term tenants to leave: ignoring repairs, turning off heat and gas, and doing nothing to eliminate mold and vermin infestations. The landlord's goal is to make the apartment so uninhabitable that residents are forced out, allowing them to deregulate the apartment and turn it over to market rate for a high profit. These actions drive up costs in the already unaffordable housing market and displace families who make up the fabric of these neighborhoods, changing communities forever. “Slumlord Millionaire,”  premieres on the PBS series VOCES on Monday, July 28, 2025, 10:00-11:30 p.m. ET (check local listings) on PBS, PBS.org and the PBS app.  

Wondering where the real estate market is heading? In this July 2025 update, we break down the latest housing trends in the Greater Philadelphia area — including Chester, Bucks, Delaware, Montgomery, South Jersey, and northern Delaware.

Antti X Antti -podcastin klassiset Flow Festival -raportit saavat tänäkin vuonna jatkoa! Toinen Anteista risteili Flow'n pyörteissä kolmen päivän ajan, nautti bändeistä ja mietti maailmanpoliittista tilannetta. Teemme yhteenvetoa musiikista, mutta myös Flow Striken vaikutuksesta, ongelmista ja mahdollisesta jatkosta. Suomimme kotimaisen median harvinaisen epäonnistunutta Flow-uutisointia, pohdimme Ruusujen taiteellista kunnianhimoa ja ihastelemma Charlie XCX:n popbriljanssia. Lopuksi toinen Anteista kohdistaa sanallisen säilänsä punk-levyjen kansiin. DIG IT!

Wes and Scott talk about the 2025 State of Devs survey, diving into trends in salaries, job titles, remote work, health, hobbies, and more. Show Notes 00:00 Welcome to Syntax! 01:44 Brought to you by Sentry.io 02:08 Years of experience vs yearly income 11:48 Layoffs 18:07 Job title 19:55 Remote work 24:40 Job happiness 25:40 Work hours 26:24 Workplace perks 26:53 What phones devs use 27:46 Desktop OS 28:44 Programming languages 29:29 Productivity apps 30:54 Social media 32:13 Median age of RSS feed users 33:41 Community contributions 35:37 Health and fitness 37:01 Health issues 39:11 Scott's health update 42:28 Hobbies 45:54 Favorite music 47:10 Favorite video games 47:37 Favorite movies 49:35 Metadata Hit us up on Socials! Syntax: X Instagram Tiktok LinkedIn Threads Wes: X Instagram Tiktok LinkedIn Threads Scott: X Instagram Tiktok LinkedIn Threads Randy: X Instagram YouTube Threads

The 401k was never designed to be your soleretirement plan—it was meant to supplement pensions, not replace them.Median 401k balance for people in their 60s?Around $112,000.-Companies love 401ks because they offload all responsibility onto the employee

A new report shows that housing costs are higher than at any other point in history ... which has many people wondering if it's time to reevaluate the American dream. On Deadline is hosted and produced by Lauren Barry and produced by Christy Strawser.

A new report shows that housing costs are higher than at any other point in history ... which has many people wondering if it's time to reevaluate the American dream. On Deadline is hosted and produced by Lauren Barry and produced by Christy Strawser.

A new report shows that housing costs are higher than at any other point in history ... which has many people wondering if it's time to reevaluate the American dream. On Deadline is hosted and produced by Lauren Barry and produced by Christy Strawser.

A new report shows that housing costs are higher than at any other point in history ... which has many people wondering if it's time to reevaluate the American dream. On Deadline is hosted and produced by Lauren Barry and produced by Christy Strawser.

A new report shows that housing costs are higher than at any other point in history ... which has many people wondering if it's time to reevaluate the American dream. On Deadline is hosted and produced by Lauren Barry and produced by Christy Strawser.

The D50 is a value that represents the median particle diameter in a sand. I calculated the D50 for 302 sands from around the world, and 15% of them are finer than the limit defined by the USGA Recommendations for a Method of Putting Green Construction.Read about this at https://www.asianturfgrass.com/post/d50-median-sand-diameter/Read more about all kinds of turfgrass topics at https://www.asianturfgrass.com/Find a suite of decision-making tools at https://www.paceturf.org/Get free ATC newsletters at https://www.asianturfgrass.com/newsletter/ Turf Without Borders show page: https://turfwb.asianturfgrass.com/International Turfgrass Society: https://turfsociety.com/

Derek Moore and Mike Snyder get into why anyone was short Opendoor and how the options market is flashing crazy implied volatility. Plus, how volatility and price movement may cause market makers to buy shares known as a “Gamma Squeeze”. Later, they get into how the signs are there that this bull market might have more to run (or not). Oh, and let's not forget to look at what the options market is forecasting for expected moves on Microsoft, Amazon, and Apple earnings next week. All this plus some recommendations this week.    Short Interest on Opendoor Implied volatility in the options for Opendoor What is a gamma squeeze? Why market makers might be forced to buy more shares to hedge when people buy calls How implied volatility, price, and time impact how many shares market makers buy Looking at a monthly breakdown of when all-time highs are reached by month Analysts are forecasting the most dissents by FOMC members at a meeting in 30 years Looking at market breadth widening Comparing the RSP equal weight ETF vs the SPY ETF performance lately Median single family home prices are holding up Why Are Stocks Up? Nobody Knows WSJ article Median S&P 500 Index Performance after 60 days above the 20-day moving average   Mentioned in this Episode   WSJ Article Why are Stocks Up? Nobody Knows https://www.wsj.com/finance/stocks/why-are-stocks-up-nobody-knows-e40e5f42?gaa_at=eafs&gaa_n=ASWzDAgNaz0DDWFH6gDHn6aERrjSRwPmYAW_gghkSG_vodoYjhptA0P1MDkxjbWf_I8%3D&gaa_ts=6884571e&gaa_sig=yozSyPX1hqhHz6UAZ2l-hgP3YdDvVJAHPTMiUXl-RbQszZ0B_F6nf5MoO9DjUl2uwotmVVavxIG3wmp2BPUwOg%3D%3D   Derek Moore's book Broken Pie Chart https://amzn.to/3S8ADNT   Jay Pestrichelli's book Buy and Hedge https://amzn.to/3jQYgMt   Derek's book on public speaking Effortless Public Speaking https://amzn.to/3hL1Mag   Contact Derek derek.moore@zegainvestments.com       

Today's poem is Sunflowers in the Median by Natalie Homer.The Slowdown is currently taking a break. We'll be back soon with new episodes from a new host. This week, we're going back into the archive to revisit Ada Limón's time as host. Today's episode was originally released on March 4, 2022. In this episode, former host Ada Limón writes… “What is it about noticing beauty that brings you out of yourself and returns you to yourself? I love rooting for beauty, for awe, for those unexpected visions that make life a little easier to manage. In today's vibrant poem, we see how the image of sunflowers can allow for a sort of grace. I love this poem for its appreciation of unexpected beauty.” Celebrate the power of poems with a gift to The Slowdown today. Every donation makes a difference: https://tinyurl.com/rjm4synp

The median home value across the state rose by two thirds in the last 4 years. Montana Free Press' Eric Dietrich crunched the numbers and joined MTPR's Elinor Smith to break them down.

A 3.73 GPA isn't the same as a 3.2—schools care about more than medians, and every point counts in the index. The solution for below-median GPAs? Crush the LSAT.Read more on our website. Email daily@lsatdemon.com with questions or comments. Watch this episode on YouTube!

Rising supply and falling demand is pushing down rents. New Cotality analysis of MBIE data shows the national median rent dropped 0.3% in the year to May. That's the first time the rent has dropped in more than 15 years. Aspire Property Management's Managing Director Mike Atkinson told Mike Hosking housing supply is increasing at the same time incomes are falling in real terms. He says there's also been a huge drop-off in net migration, with fewer people coming into the country. However, there could be some good news on the way for landlords. Atkinson says things should pick up over summer, when migration typically increases. LISTEN ABOVE See omnystudio.com/listener for privacy information.

„Motoristé nemají žádné velké pevné přesvědčené jádro voličů. Mají jádro, které je ochotné na Filipa Turka pracovat, hájit ho, ozývat se. Podobně jako třeba KDU-ČSL na Moravě. Ale nebude to stačit,“ myslí si sociolog Buchtík. Strana, která na víkend svolává krizový sněm, podle něj potřebuje nutně oslovit další skupiny voličů. Můžou ještě Motoristé poznamenaní kauzami Filipa Turka otočit negativní trend? Jak se tři měsíce před volbami daří dalším menším stranám? A dá se odhadnout, kolik hlasů letos propadne? Téma pro Marii Bastlovou a sociologa a šéfa výzkumné agentury STEM Martina Buchtíka v dalším díle speciálu Ptám se já – Rok voleb, ve kterém spolu pravidelně až do volebního víkendu glosují nejzásadnější témata a momenty letošního klání o křesla v Poslanecké sněmovně.Poslední volby do Sněmovny v roce 2021 se zapsaly do historie jako volby, ve kterých propadlo nejvíc hlasů. Volilo sice skoro 5,4 milionu lidí a volební účast překročila 65 procent. Přes milion Čechů se ale rozhodlo pro strany, kterým se nakonec nepodařilo překročit pětiprocentní limit pro vstup do dolní komory. Zhruba každý pátý hlas tak propadl. Voliči si to podle sociologa Martina Buchtíka velmi dobře uvědomují a o to víc rozvažují, zda stranám pohybujícím se kolem pěti procent dají svůj hlas. „Určitě je pravda, že to lidi zvažují. Vidíme to dlouhodobě u Zelených, kteří mají docela dobrou potenciální základnu potenciálních lidí, kteří by je zvažovali. Ale potom si řeknou: ‚Vlastně Zelení se tam nedostanou. Tak já je volit nebudu, byl by to hlas, který připadne třeba komunistům.‘“„A zároveň taky vidíme, že třeba v minulých sněmovních volbách nebo hlavně v prezidentských volbách, kdy pro ně byl Andrej Babiš hlavní oponent, lidé chtěli zvolit co nejsilnějšího protikandidáta. Což byla ve sněmovních volbách koalice Spolu a v prvním kole prezidentské volby Petr Pavel. Přiklonili se k tomu silnějšímu hráči, který měl v jejich očích větší pravděpodobnost porazit Andreje Babiše,“ říká sociolog a dodává:„Ten milion (propadnutých hlasů) se asi nezopakuje. To byla zcela výjimečná situace. Ale půl milionu by to být mohlo. Přeliv na poslední chvíli bude strašně důležitý. Budou také důležité finální debaty, kam se dostanou asi jenom ty největší politické strany.“Motoristům by pomohlo spojení s Přísahou Kolem pěti procent se tři měsíce před volbami pohybují Motoristé, kteří kvůli tomu na tento víkend svolali krizový sněm. Podle aktuálního modelu STEM by teď získali 3,5 procenta, před týdnem to byla čtyři procenta. Červnový model agentury Median připsal straně 5,5 procenta, od února do dubna se přitom v průzkumech Medianu pohybovali o několik procent výš.„Je to dané tím, že to není samostatná strana, ale je to do velké míry strana voličů Filipa Turka. A Filip Turek se v posledních měsících potýká, když to řekneme kulantně, s řadou reputačních problémů. A neřeší je úplně dobře,“ myslí si Buchtík. Znamená to, že by byl Turek už odepsaný? „To určitě neznamená, ale nemá tu pozici prostě jednoduchou. Motoristé nemají žádné velké pevné přesvědčené jádro. Mají jádro, které je ochotné na Filipa Turka pracovat, hájit ho, ozývat se, roznášet letáky. Podobně to má třeba KDU-ČSL, taky mají silnou základnu, která je zejména na Moravě ochotná straně věnovat svůj volný čas. Samozřejmě dost rozdílně než podporovatelé Filipa Turka. Ale nebude to stačit,“ poznamenává sociolog. Strana podle něj nemůže jen upevňovat své voličské jádro, ale nutně potřebuje oslovit další skupiny. V tom by jí mohlo pomoci spojení s Přísahou Róbera Šlachty, se kterou Motoristé loni kandidovali do evropských voleb a získali právě mandát pro Turka. Strany se ale rozešly ve zlém a Přísaha oznámila, že do Sněmovny půjde samostatně. Aktuálně se ovšem spekuluje, že by ještě přece jen mohlo dojít k opětovnému spojení těchto dvou subjektů. Čas mají do konce července, kdy se odevzdávají kandidátky. Stačilo! se může posunout od pětiprocentní hraniceHnutí Stačilo!, ve kterém figurují komunisté v čele s Kateřinou Konečnou, si chce překonání pětiprocentní hranice do Sněmovny pořádně pojistit. I díky spojení s dalšími subjekty zapsalo hnutí úspěch v loňských evropských volbám. Do těch parlamentních teď posílí o sociální demokraty, se kterými se po zprvu neúspěšných námluvách nakonec dohodlo tento týden. Průzkumy nyní hnutí Stačilo! připisují zhruba pět procent, sociální demokraté by se nepřehoupli ani nad tři procenta.„(Díky členům SOCDEM na kandidátkách) může Stačilo! získat třeba půl procenta nebo jeden procentní bod navíc. Což je důležité. A taky by je to aspoň vizuálně posunulo od té pětiprocentní hranice, na které teď dlouhodobě jsou. To je taky důležitý prvek. Už nebudou plýtvat energií na přesvědčování, že se tam dostanou, ale začnou komunikovat něco jiného. Zajímavé potom bude, jak se vzájemně budou kroužkovat ty dvě voličské skupiny,“ komentuje Buchtík a pokračuje:„Myslím, že se do Sněmovny spíš dostanou. Ale kromě spojení se sociálními demokraty bude rozhodovat to, jakou rétoriku zvolí SPD a také jestli Stačilo! udrží tu dvouhlavou saň, to znamená Kateřinu Konečnou a Daniela Sterzika, tak, aby mluvili zhruba stejně i těsně před volbami.“Rýsuje se už složení budoucí Sněmovny? A které známé tváře z menších stran by se mohly objevit v příští vládě? --V bonusovém projektu pořadu Ptám se já – Rok voleb moderátorka Marie Bastlová a sociolog Martin Buchtík glosují zásadní trendy a témata letošních sněmovních voleb. Sledujte na Seznam Zprávách, poslouchejte na Podcasty.cz a ve všech podcastových aplikacích.Archiv všech dílů najdete tady. Své postřehy, připomínky nebo tipy nám pište prostřednictvím sociálních sítí pod hashtagem #ptamseja nebo na e-mail: audio@sz.cz.

Median home pricing at $400,000? We need answers! So we talked to Andy Babula who is a professor of Real Estate and Finance with the Opus College of Business at the University of St. Thomas about why the housing market is so high - in fact the first time it has hit $400,000 ever! Then we discuss the latest addition to your Minnesota Twins uniforms! Also, in DeRush Hour News Headlines we honor the closing of Edina Grill after three decades, high paying jobs where you can make a haul of cash and much more!

Podle agentury Median u nás letos klesl historicky na nejnižší úroveň zájem o volby. Ještě před dvěma lety chtělo jít k volbám skoro 80 procent dotázaných. Počátkem letošního roku jenom něco málo přes 60 procent, v dubnu 54, v květnu už jen 53 procent. Trend je zřetelně klesající.

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Big O talks Crypto 062725

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Don tackles a stack of listener questions in this rapid-fire Friday Q&A, covering what a financial plan should cost, how tipping might work in a cashless future, and how to fine-tune a retirement portfolio with Avantis funds. He also addresses important estate planning steps after a death, how to use QCDs with inherited IRAs, and whether AUM fees are worth it compared to hourly planners. Along the way, he reflects on why he still manages his own money—and maybe shouldn't. 0:04 Intro to Friday Q&A and how listener questions are selected 2:12 What should a detailed retirement plan cost? Median price range explained 4:33 How will we tip in a cashless society? From bellboys to Bitcoin to Apple Pay 7:39 Listener portfolio check: 85% AVGE, 10% AVUV, 5% AVDV—too tilted? 11:36 Credit after death: Should an executor notify the credit bureaus? Yes—and how 13:45 Inherited IRA RMD workaround: Can QCDs help avoid taxes before age 70½? 17:02 AUM fees vs. flat-fee advisors: Is paying more for more assets fair? 25:51 Why Don still manages his own money (for now)—inertia, taxes, and habits Learn more about your ad choices. Visit megaphone.fm/adchoices

최근 실시된 글로벌 조사에서 호주가 성인 1인당 중간 재산(Median wealt) 기준 세계 2위를 기록했습니다.

Mathias ist Vorstandsvorsitzender von Axel Springer, Medienmanager, Autor und Journalist. Und vor allem ist er laut ChatGPT auf Platz 2 der mächtigsten Medienmänner weltweit. Ich wollte von ihm wissen, wie seine Biografie ihn geprägt hat, welche Werte er mit Freiheit verbindet und wie sich das eigene Verhältnis zu Geld verändert, wenn man Milliardär ist. Außerdem habe ich mich gefragt, was seine heutige Sicht auf den Fall Julian Reichelt ist. Wir sprechen über Macht, Vertrauen, Zweckpessimismus, es geht um Widerstand, Mut, Risiko, Diskussionskultur und familiäre Werte. WERBEPARTNER & RABATTE: https://linktr.ee/hotelmatze MEIN GAST: https://ullstein.de/urheberinnen/mathias-doepfner DINGE: Nile Rodgers - Le Freak: https://thalia.de/shop/home/artikeldetails/A1020984635 Benjamin von Stuckrad-Barre - Noch wach?: https://thalia.de/shop/home/artikeldetails/A1064678458 Maximilian Frisch - Produktion Torben Becker - Redaktion Lena Rocholl - Redaktion Mit Vergnügen - Vermarktung und Distribution MEIN ZEUG: Mein neues Fragenset: https://beherzt.net/liebe Mein neues Buch: https://bit.ly/3cDyQ18 Die Hotel Matze Suite bei Apple: https://apple.co/43V3hGq Die Hotel Matze Suite bei Spotify: https://spoti.fi/3U3ZySC Wunschgäste bitte in die Kommentare: https://apple.co/2RgJVH6 Mein Newsletter: https://matzehielscher.substack.com/ TikTok: https://tiktok.com/@matzehielscher Instagram: https://instagram.com/matzehielscher LinkedIn: https://linkedin.com/in/matzehielscher/ YouTube: https://bit.ly/2MXRILN Twitter: https://twitter.com/hotelmatze1 Mein erstes Buch: https://bit.ly/39FtHQy Mein erstes Fragenset: https://beherzt.net/matze

MDJ Script/ Top Stories for June 6th Publish Date:  June 6th    Commercial: From the BG AD Group Studio, Welcome to the Marietta Daily Journal Podcast.    Today is Friday, June 6th and Happy Birthday to Tommie Smith I’m Keith Ippolito and here are the stories Cobb is talking about, presented by Times Journal New $50,000 Median to Drive Safety on Fairground Street Attempted Carjacking Suspect Held at Gunpoint by Civilian, Arrested in Marietta Kennesaw’s Salute to America is July 3 Plus, Leah McGrath from Ingles Markets on controlling your sweet tooth All of this and more is coming up on the Marietta Daily Journal Podcast, and if you are looking for community news, we encourage you to listen and subscribe!  BREAK: TOP TECH MECHANICAL STORY 1: New $50,000 Median to Drive Safety on Fairground Street Marietta is enhancing road safety with a new median on Fairground Street near Haley Street. The $50,000 project, set to finish next week, aims to prevent U-turns that have caused accidents and traffic issues. The median will allow only left turns off Fairground Street, with 200 feet of median and 115 feet of curb being installed. Signage will alert drivers to the changes, ensuring smoother and safer traffic flow. STORY 2: Attempted Carjacking Suspect Held at Gunpoint by Civilian, Arrested in Marietta A carjacking suspect, Rico Riley, was arrested in Marietta after a witness, Gary Edwards, intervened and held him at gunpoint. Riley allegedly attempted to steal two cars at a Chevron gas station on Franklin Gateway. He first fought a woman for her car keys, then tried to carjack a second vehicle with a family inside. Edwards intervened both times, ultimately detaining Riley until police arrived. Riley faces multiple felony charges, including attempted armed robbery and child cruelty, and is held without bond. Marietta Police commend Edwards but urge witnesses to prioritize safety and call 911 in such situations. STORY 3: Kennesaw’s Salute to America is July 3 Kennesaw's annual Independence Day celebration, **Salute to America**, takes place July 3 from 6–10 p.m. in downtown Kennesaw. The free event features live music, food vendors, family activities, and a fireworks finale at 9:30 p.m. Performances include Tripp’n at 6 p.m., Girls Night Out at 7 p.m., and Guardians of the Jukebox at 8 p.m. Kids can enjoy ticketed inflatables, and food and drinks will be available for purchase. Reserved seating is $20, with reservations at kennesawjuly3.com. Tobacco and e-cigarettes are prohibited, and the event may be rescheduled for bad weather. We have opportunities for sponsors to get great engagement on these shows. Call 770.799.6810 for more info.  Break: Ingles Markets 2 STORY 4: Update: Asylum Seeker Married to Alpharetta Man Released on Bond Colombian asylum seeker Daniela Landin, 24, was released on a $10,000 bond after nearly a month in ICE custody. Married to Alpharetta resident Richard Landin, she fled gang violence in Colombia and sought asylum last year, though her initial request was denied and is under appeal. ICE detained her in May, citing an issue with her ankle monitor, despite it functioning properly. Her bond was granted after a delayed hearing, with the judge convinced of her sincerity and low flight risk. The couple, unable to fly due to her lack of ID, is driving back to Georgia, relieved to reunite. STORY 5: OUT AND ABOUT: 5 Things to Do This Weekend in Cobb County — June 6 - 8 This weekend in Cobb County offers a variety of events: Marietta Square hosts its free Art Walk Friday from 5-9 p.m., showcasing local art alongside shopping and dining. The BLADE Show at Cobb Galleria Centre runs Friday-Sunday, featuring unique blades and collectibles, with tickets starting at $30. The Kennesaw Grand Prix 5K kicks off Saturday at 8 a.m., followed by a post-race party. The Strand Theatre presents "Grease" with showtimes through June 22, and Swift-Cantrell Park in Kennesaw screens "Moana 2" Saturday at 8:15 p.m., with pre-movie activities starting at 6 p.m. Break: And now here is Leah McGrath from Ingles Markets on controlling your sweet tooth We’ll have closing comments after this. Break: TIDWELL TREES Signoff-   Thanks again for hanging out with us on today’s Marietta Daily Journal Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at mdjonline.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com tidwelltrees.com toptechmech.com #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversations See omnystudio.com/listener for privacy information.

Median house prices hit $1 million across capital cities, government taxes blamed for reigniting Australia’s tobacco wars. Plus, Erin Patterson takes the stand in her mushroom poisoning murder trial.See omnystudio.com/listener for privacy information.

Welcome to the "Saturday Morning Golf Stat" from the Hack it Out Golf Podcast. You've missed the green in the rough, but you're still hoping to get up and down and save a score. How far are you likely to end up from the hole when you're 35 yards away and in the rough? In this episode, Lou quizzes Mark and Greg on median distance by handicap. Afterwards, they reiterate why you need to be aware of what a good shot really is—and how expectation management can increase your performance on the course. Each of these will be a mini-episode (10-15 minutes long) about an interesting golf stat. We will discuss what you can learn, and most importantly, how you can apply this on the golf course to lower your scores and lower your handicap. Listen on your drive to the golf course or over your Saturday morning coffee! Data is sourced from Arccos Golf. They have over 1 BILLION shots in their database.  Check them out at: https://www.arccosgolf.com/  Use code DATALOU15 for 15% off! Learn more about your ad choices. Visit megaphone.fm/adchoices

What will the impact be now that the U.S. has one of the highest tariff rates in the world?Topics covered include:Why the Trump administration raised tariffsHow the last round of U.S. tariffs led to higher prices and lower economic growthFour ways the world remains close to record connectivityWho have been the winners and losers from global tradeWhat will be the impact of this trade warEpisode SponsorsDelete Me – Use code David20 to get 20% offInsiders Guide Email NewsletterGet our free Investors' Checklist when you sign up for the free Money for the Rest of Us email newsletterOur Premium ProductsAsset CampMoney for the Rest of Us PlusShow NotesThe economic consequences of Mr Trump – looking for clarity in the tariffs chaos by Neil Shearing—Capital EconomicsTariff rate, most favored nation, simple mean, all products (%)—World Bank GroupDonald Trump's tariffs will fix a broken system by Peter Navarro—The Financial TimesDHL Global Connectedness Tracker—DHLObjective Knowledge: An Evolutionary Approach by Karl R. Popper—Oxford University PressGDP per capita (constant 2015 US$)—World Bank GroupJOSEPH E. STIGLITZ, GLOBALIZATION AND ITS DISCONTENTS REVISITED: ANTI-GLOBALIZATION IN THE ERA OF TRUMP, NEW YORK: W.W. NORTON & COMPANY, 2018 by Lino Sau—Annals of the Fondazione Luigi EinaudiFIFTY YEARS OF GROWTH IN AMERICAN CONSUMPTION, INCOME, ANDWAGES by Bruce Sacerdote—National Bureau of Economic ResearchReal Median Household Income in the United States—FREDEmployed full time: Median usual weekly real earnings: Wage and salary workers: 16 years and over—FREDConsumer Price Index for All Urban Consumers: Food in U.S. City Average/Median Household Income in the United States—FREDTrump's Love for Tariffs Began in Japan's '80s Boom By Jim Tankersley and Mark Landler—The New York TimesRelated Episodes515: Tariffs and the Mar-a-Lago Accord: What Trump Really Wants516: What Trump Wants Part 2 – How Trade Deficits and Capital Flows Can Harm or Help Countries427: Did the Tariffs Work? The Trade War Five Years Later212: Trade Wars Increase Prices and PovertySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Home prices are falling fast in some prime real estate markets across the country while others remain stubbornly stuck. What's the defining factor between a stable housing market and one where sellers are actively cutting prices? Housing inventory! This metric defined the 2020 - 2022 run-up in home prices, but the rubber band of demand is snapping back as buyer power grows, housing inventory rises, and investors get even better buying opportunities. Remember when people said, “I'll buy when prices drop”? Well, now might be the time. ResiClub's Lance Lambert joins us to provide a holistic view of housing inventory, prices, demand, and emerging opportunities. Lance walks through the most up-to-date data on where housing inventory is rising fast, where prices are quickly declining, and which markets are holding on as sellers remain in control. We'll also talk about why homebuilding costs are about to JUMP and the reason Warren Buffett sold his homebuilding stocks shortly after buying them. Will construction slow down, limiting new inventory and leading us back into ultra-low supply? If so, this could push home prices higher, creating a prime opportunity for real estate investors. In This Episode We Cover: Is spiking inventory a worrying sign for the housing market, or are we merely normalizing? What to look at in your housing market to forecast whether prices will rise or fall  Why are homebuilding costs about to JUMP, and could this lead to even more inventory problems? The new housing trend: Older renters, but could this mean more demand for rentals? And So Much More! Links from the Show Join BiggerPockets for FREE Let Us Know What You Thought of the Show! Ask Your Question on the BiggerPockets Forums BiggerPockets YouTube Apply to Be a BiggerPockets Real Estate Guest ResiClub: The cost breakdown for constructing a single-family home in 2024 ResiClub: Did Warren Buffett see this coming? Homebuilder margins face pressure in 2025 ResiClub: The vanishing young homebuyer: Median first-time homebuyer age jumps from 28 in 1991 to 38 in 2024 Invest in Private Market Real Estate with the Fundrise Flagship Fund Grab Dave's Book, “Real Estate by the Numbers” Sign Up for the BiggerPockets Real Estate Newsletter Find an Investor-Friendly Agent in Your Area Inventory Is Key to a Stable Real Estate Market—Will It Recover? Join Lance's Newsletter Connect with Dave Check out more resources from this show on BiggerPockets.com and https://www.biggerpockets.com/blog/real-estate-1101 Interested in learning more about today's sponsors or becoming a BiggerPockets partner yourself? Email advertise@biggerpockets.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Primal Potential Podcast, we're diving into three powerful but simple strategies to help you optimize your blood sugar, improve your insulin sensitivity, and increase your energy levels. These are real-world, easy-to-implement hacks that go beyond the usual “eat less sugar” advice. Before we get started, grab your copy of my new Fat Loss E-Book! Here's the link. And, head over to my new YouTube channel to subscribe and turn on notifications before the new Carb Series kicks off next week.  Hack #1: Get Sunlight First Thing in the Morning ☀️ Did you know that getting direct sunlight within the first hour of waking helps reset your circadian rhythm, which plays a major role in blood sugar regulation and insulin sensitivity? Pairing this with light movement (like a 10-minute walk or some gentle stretching) can improve how efficiently your body uses glucose before breakfast. What the Science Says: On average, exposure to sunlight improved insulin sensitivity by 18.75%. Median improvement was 18%, meaning half of people experienced even greater benefits. Range of effects: Sunlight exposure improved insulin function by 15-22%. Glucose tolerance: Participants who got more sunlight saw a 12-16% improvement in how well their bodies processed carbohydrates.